^
Association details:
| Biomarker: | FLT4 R1324L |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | Votrient (pazopanib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)
Excerpt:
Two VEGFR3 missense polymorphisms, VEGFR3 rs307821 (R1324L) and VEGFR3 rs307826 (T494A), showed a trend toward reduced PFS in GEP NETs (HR: 12.3; 95% CI 1.09–139·2; P = 0.042 and HR: 6.9; 95% CI 0.96–49.9; P = 0.055...Pazopanib showed clinical activity in patients with advanced NETs regardless of previous treatments.
DOI:
10.1093/annonc/mdv252
Trial ID:
